(Q36856816)

16 August 2017

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study (English)

1 reference

16 August 2017

6

Axel Le Cesne

0 references

Jean-Yves Blay

5

Jean-Yves Blay

0 references

Roberta Sanfilippo

Roberta Sanfilippo

7

0 references

Carlo Spreafico

Carlo Spreafico

11

0 references

Silvia Stacchiotti

Silvia Stacchiotti

12

0 references

Elena Tamborini

Elena Tamborini

13

0 references

Paola Collini

Paola Collini

9

0 references

Alessandro Gronchi

Alessandro Gronchi

17

0 references

Paolo Giovanni Casali

Paolo G Casali

20

0 references

Maurizio D'Incalci

Maurizio D'Incalci

16

0 references

Federica Grosso

1

Federica Grosso

1 reference

16 August 2017

19

Silvana Pilotti

1 reference

16 August 2017

3

George D Demetri

1 reference

16 August 2017

2

Robin L Jones

1 reference

16 August 2017

4

Ian R Judson

1 reference

16 August 2017

14

Juan Carlos Tercero

1 reference

16 August 2017

10

Palma Dileo

1 reference

16 August 2017

Paola Casieri

8

1 reference

PubMed ID

17586092

16 August 2017

Josè Jimeno

15

1 reference

PubMed ID

17586092

16 August 2017

Jonathan A Fletcher

18

1 reference

16 August 2017

1 July 2007

1 reference

Lancet Oncology Commission

16 August 2017

1 reference

16 August 2017

8

1 reference

16 August 2017

595-602

1 reference

16 August 2017

7

1 reference

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

A novel FUS/CHOP chimera in myxoid liposarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Myxoid liposarcoma--the frequency and the natural history of nonpulmonary soft tissue metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Management of soft-tissue sarcomas: an overview and update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Differential sensitivity of liposarcoma subtypes to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Myxoid liposarcoma. Experience with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

Imatinib mesylate in chordoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970175-4

7 January 2021

10.1016/S1470-2045(07)70175-4

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17586092